Literature DB >> 16888250

Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus.

Hiroki Yokoyama1, Naoto Katakami, Yoshimitsu Yamasaki.   

Abstract

BACKGROUND AND
PURPOSE: Type 2 diabetes is associated with a high cardiovascular morbidity and mortality. Recent advances of intervention studies in type 2 diabetes with use of carotid intima-media thickness (CIMT) measurement as a surrogate end point may allow for better understanding of the undetermined process of atherosclerosis, the effect of interventions, and the usefulness of CIMT to inhibit events of cardiovascular disease. SUMMARY OF REVIEW: Data were available from 11 studies (n=1578) in subjects with type 2 diabetes (including impaired glucose tolerance, n=132) that evaluated the effect of interventions on change in CIMT. The overall weighed rate of change in mean CIMT based on data among control groups (ie, type 2 diabetes without interventions) was 0.034 mm/y (95% CI, 0.029 to 0.039; median SD, 0.054), in which mean HbA(1c) was 7.86% (95% CI, 7.72 to 8.00; median SD, 1.5). A significant close correlation of HbA(1c) with rate of CIMT change was found (R(2)=0.35, P=0.01). Agents for lowering of blood glucose, platelet activation, or blood pressure significantly reduced the CIMT increase, independent of blood glucose control. This implies that other mechanisms of such agents to diminish CIMT increase should be explored.
CONCLUSIONS: CIMT measurement may contribute to elucidating the short- and/or long-term effect of interventions on the rate of change in CIMT in relation to the levels of various risk factors. Although the method needs further standardization, pharmacological interventions are likely to inhibit progression of CIMT, leading to a reduction of cardiovascular events.

Entities:  

Mesh:

Year:  2006        PMID: 16888250     DOI: 10.1161/01.STR.0000236632.58323.cd

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  26 in total

1.  Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data.

Authors:  Theodore Mazzone
Journal:  Circulation       Date:  2010-11-23       Impact factor: 29.690

2.  Impact of kidney function and urinary protein excretion on intima-media thickness in Japanese patients with type 2 diabetes.

Authors:  Yusuke Nakade; Tadashi Toyama; Kengo Furuichi; Shinji Kitajima; Yoshiyasu Miyajima; Mihiro Fukamachi; Akihiro Sagara; Yasuyuki Shinozaki; Akinori Hara; Miho Shimizu; Yasunori Iwata; Hiroyasu Oe; Mikio Nagahara; Hiroshi Horita; Yoshio Sakai; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2015-02-03       Impact factor: 2.801

Review 3.  Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis.

Authors:  Hideaki Kaneto; Naoto Katakami; Munehide Matsuhisa; Taka-aki Matsuoka
Journal:  Mediators Inflamm       Date:  2010-02-16       Impact factor: 4.711

4.  Differential effect of concomitant antidiabetic agents on carotid atherosclerosis: a subgroup analysis of the PROLOGUE study.

Authors:  Atsushi Tanaka; Atsushi Kawaguchi; Jun-Ichi Oyama; Tomoko Ishizu; Hiroshi Ito; Jun Fukui; Taizo Kondo; Shigetaka Kuroki; Mamoru Nanasato; Yukihito Higashi; Kohei Kaku; Teruo Inoue; Toyoaki Murohara; Koichi Node
Journal:  Heart Vessels       Date:  2018-10-03       Impact factor: 2.037

5.  Association of arterial stiffness with HbA1c in 1,000 type 2 diabetic patients with or without hypertension.

Authors:  Yuhong Chen; Yun Huang; Xiaoying Li; Min Xu; Yufang Bi; Yu Zhang; Weiqiong Gu; Guang Ning
Journal:  Endocrine       Date:  2009-07-14       Impact factor: 3.633

6.  Thiazolidinedione Derivatives: In Silico, In Vitro, In Vivo, Antioxidant and Anti-Diabetic Evaluation.

Authors:  Manal Y Sameeh; Manal M Khowdiary; Hisham S Nassar; Mahmoud M Abdelall; Hamada H Amer; Abdelaaty Hamed; Ahmed A Elhenawy
Journal:  Molecules       Date:  2022-01-27       Impact factor: 4.411

7.  Is A1C Variability an Independent Predictor for the Progression of Atherosclerosis in Type 2 Diabetic Patients?

Authors:  Chul Sik Kim; So Young Park; Sung Hoon Yu; Jun Goo Kang; Ohk Hyun Ryu; Seong Jin Lee; Eun Gyung Hong; Hyeon Kyu Kim; Doo-Man Kim; Jae Myung Yoo; Sung Hee Ihm; Moon Gi Choi; Hyung Joon Yoo
Journal:  Korean Diabetes J       Date:  2010-06-30

8.  Discovery Potent of Thiazolidinedione Derivatives as Antioxidant, α-Amylase Inhibitor, and Antidiabetic Agent.

Authors:  Manal Y Sameeh; Manal M Khowdiary; Hisham S Nassar; Mahmoud M Abdelall; Suliman A Alderhami; Ahmed A Elhenawy
Journal:  Biomedicines       Date:  2021-12-23

9.  Impact of different antihypertensives on carotid arterial wall thickness.

Authors:  Ki-Hong Kim; In Geol Song; Taek-Geun Kwon; Jeong Bae Park; Kee-Sik Kim; Wuon-Shik Kim; Jang-Ho Bae
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-04       Impact factor: 3.738

10.  Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease.

Authors:  Taeang Arai; Masanori Atsukawa; Akihito Tsubota; Keizo Kato; Hiroshi Abe; Hirotaka Ono; Tadamichi Kawano; Yuji Yoshida; Tomohide Tanabe; Tomomi Okubo; Korenobu Hayama; Ai Nakagawa-Iwashita; Norio Itokawa; Chisa Kondo; Keiko Kaneko; Naoya Emoto; Mototsugu Nagao; Kyoko Inagaki; Izumi Fukuda; Hitoshi Sugihara; Katsuhiko Iwakiri
Journal:  Sci Rep       Date:  2021-08-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.